Literature DB >> 8147093

Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.

B Christenson1, M Böttiger.   

Abstract

A two-dose vaccination programme, using a combined measles, mumps and rubella vaccine (MMR) and administration at the ages of 18 months and 12 years, was introduced into Sweden in 1982. Since the combined MMR vaccine was introduced, a yearly evaluation of the immunity patterns and seroconversion rates in 12-year-old children has been carried out. This study includes three study groups. All groups consisted of pre- and postvaccination samples from 12-year-old children taken in connection with the MMR immunization. There were 332 paired samples from children who 8-10 years previously had received live measles vaccine. Prevaccination sera from these children represent late postvaccination titres. The postvaccination sera of 49 children seronegative to measles before vaccination, obtained 2 months after vaccination, represent early postvaccination immunity. Ninety-five children who had not been vaccinated earlier and who were seropositive to measles represent naturally acquired immunity. All samples were studied by an enzyme-linked immunosorbent assay (ELISA). Sera from children with late postvaccination immunity had significantly lower titres than children in group 2, who represented early postvaccination sera (p < 0.001). Children with naturally acquired immunity had significantly higher titres than children with vaccine-induced immunity titres (p < 0.001). After revaccination of the previously vaccinated children, a significant booster rise was seen (p < 0.001). After revaccination of children with naturally acquired immunity, no significant booster effect was observed. Sixty-five children of the 332 (20%) previously vaccinated children had no or borderline measles titres prior to the booster. The study suggests that the vaccine-induced measles antibodies decline with time and may fall under the protective level.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147093     DOI: 10.1016/0264-410x(94)90049-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

2.  Measles immunity and response to revaccination among secondary school children in Cumbria.

Authors:  N Calvert; F Cutts; R Irving; D Brown; J Marsh; E Miller
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

3.  Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques.

Authors:  Ashley N Nelson; Wen-Hsuan W Lin; Rupak Shivakoti; Nicole E Putnam; Lisa Mangus; Robert J Adams; Debra Hauer; Victoria K Baxter; Diane E Griffin
Journal:  JCI Insight       Date:  2020-02-13

Review 4.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

5.  Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children.

Authors:  Yuanbao Liu; Peishan Lu; Ying Hu; Zhiguo Wang; Xiuying Deng; Fubao Ma; Hong Tao; Chengmei Jia; Xiaoyan Ding; Haitao Yang; Pei Liu; Jie Min
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

6.  Effectiveness assessment of vaccination policy against measles epidemic in Japan using an age-time two-dimensional mathematical model.

Authors:  Yusuke Maitani; Hirofumi Ishikawa
Journal:  Environ Health Prev Med       Date:  2011-05-07       Impact factor: 3.674

7.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

Review 8.  Measles Resurgence and Drug Development.

Authors:  Richard K Plemper
Journal:  Curr Opin Virol       Date:  2020-04-01       Impact factor: 7.090

9.  Gender effects on humoral immune responses to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Margaret A K Ryan; Gregory A Poland
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

10.  Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.

Authors:  Piyanit Tharmaphornpilas; Pornsak Yoocharean; Aim-Orn Rasdjarmrearnsook; Apiradee Theamboonlers; Yong Poovorawan
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.